Latest news articles

Added 10 days ago Drug news

EMA approves Hemlibra for routine prophylaxis in haemophilia A

Roche announced that the European Commission has approved Hemlibra (emicizumab) for routine prophylaxis of bleeding episodes in people with severe...

Added 26 days ago Drug news

EU approves Mulpleta for severe thrombocytopaenia.- Shionogi

The European Commission (EC) has granted marketing approval for Mulpleta (lusutrombopag), from Shionogi, for the treatment of severe thrombocytopaenia in...

Added 1 month ago Drug news

FDA approves Esperoct to treat haemophilia A.- Novo Nordisk

Novo Nordisk announced that the FDA has approved the Biologics License Application for Esperoct for the treatment of adults and...

Search all news articles for Coagulation and haemorrhagic disorders
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Oral Anticoagulation Reversal

Oral Anticoagulation Reversal

Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Load more

Guidelines

BSH Guideline: management of thrombotic and haemostatic issues in paediatric malignancy

Venous thromboembolism (VTE) and bleeding are serious complications of cancer and its treatment. A recent survey of UK paediatric haematologists and oncologists identified a broad variety of practice in the management of issues...

Added 1 year ago

Guidelines for the management of acute joint bleeds and chronic synovitis in haemophilia: A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline.

Evidence-based guidelines were developed summarizing best practice for the assessment and management of acute joint bleeds and chronic synovitis in persons with haemophilia.

Added 9 months ago

A practical guideline for the haematological management of major haemorrhage

The aim of these updated guidelines is to provide recommendations for the haematological management of major haemorrhage in any clinical situation...

Added 3 years ago

Search all guidelines for Coagulation and haemorrhagic disorders
 

Journal articles

Non-Vitamin K Oral Anticoagulants Associated Bleeding and Its Antidotes.

Oral anticoagulant-associated intracerebral hemorrhage (OAC-ICH) accounts for nearly 20% of all ICH. The number of patients with an indication for oral anticoagulant therapy (OAT) increases with increasing age.

Added 20 hours ago

Reversal Strategies for Intracranial Hemorrhage Related to Direct Oral Anticoagulant Medications.

Direct oral anticoagulants (DOACs) are a new class of anticoagulants that directly inhibit either thrombin or factor Xa in the coagulation cascade. They are being increasingly used instead of warfarin or other vitamin K antagonists (VKAs).

Added 4 days ago

Andexanet Alfa for Reversing Factor Xa Inhibition.

One obstacle for the more widespread use of the DOACs in clinical practice has been the lack of a reversal agent. Most DOACs act by directly binding to and inhibiting the effects of factor Xa.

Added 4 days ago

Search all journal articles for Coagulation and haemorrhagic disorders
 

Clinical trials

Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (HAVEN 5)

This randomized, multicenter, open-label, Phase 3 study is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII (FVIII) inhibitor status.

Added 1 year ago

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)

This multicenter, open-label, non-randomized study will assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at a dose of 6 milligrams per kilogram (mg/kg) every 4 weeks...

Added 1 year ago

A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)

This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older.

Added 1 year ago

Search all clinical trials for Coagulation and haemorrhagic disorders
 

CME

Dermatological emergencies in children

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
1
Registration required
1
Subscription fee
0

Survival guide: safe prescribing for surgical inpatients

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90

Starting patients on oral anticoagulants in primary care: how to do it

Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
90
Search all CME for Coagulation and haemorrhagic disorders